Tenofovir alafenamide fumarate

Tenofovir alafenamide fumarate (CAS No.: 379270-38-9) is a synthetic small molecule and phosphonamidate prodrug form of tenofovir that is broadly classified in antiviral discovery research as a nucleotide analog reverse transcriptase inhibitor scaffold, and it is primarily used as a biochemical and cell biology tool to investigate intracellular prodrug activation, nucleotide metabolism, and suppression of viral reverse transcription in HIV related experimental systems; mechanistically, it undergoes intracellular enzymatic conversion to tenofovir and subsequently to the active diphosphate metabolite, which competes with natural deoxynucleotide substrates at viral reverse transcriptase and terminates DNA chain elongation, thereby supporting pathway level studies of viral replication dynamics, nucleotide utilization, and host dependent prodrug processing, while comparative profiling versus related tenofovir prodrugs is commonly used to examine differential cellular loading and exposure patterns in vitro; reported antiviral potency for this class is generally characterized within nanomolar to low micromolar concentration ranges depending on cell type, viral strain, and assay design, and research applications include cell based antiviral assays, mechanistic time of addition studies, resistance and mutation mapping workflows, pharmacology focused studies in relevant animal models, and preclinical screening cascades in which the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.